High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population

Table 4 Comparison of different selection criteria for BRCA1/2 testing in our cohort

Criteria	Sensitivity	Specificity	Accuracy
NCCN	100%	50%	64%
Manchester scoring system	85.7%	88.9%	87.5%
Swedish Breast cancer group	57.1%	88.9%	75%

ISSN: 1897-4287